Thank call good to you, joining everyone on the Caroline, afternoon and us today.
and we today's provide will quarter strategic priorities, During operational I on market an on on recent business our our I as up what our also developments. clinical, on well and provide of details some year. and today. seeing are comment will rest update results our our dynamics you commercial as in as some market with perspective David well third update call, as for the results, financial the on key will outlook follow
our to product our areas the Before continues dive be into in like QX build commentary the and heart therapy. I three well therapy heart left our key environment access, and left external we heart core by breadth I'd technology Are and access to of product line team electrophysiologists quarter the mapping very during to accomplishments the by on structural and rapidly on out each line. of operating as received focus specialists guidance results, continue
offering narrow refined Over this over SKUs product SKUs XX the and today. we a from just of past expanded have year, five line to
Europe. of help software be calls rapidly of an particularly will results seeing that where large atrial and helpful persistent QX for automatically into in Ablation Catheter Sensing cardiac revealing this software commercial growth remain around fibrillation, traction our therapy, interest customers, is QX. annualizing physician $X in crossing insights and with Force million and tissue. now In the our further each regions we better that line tailor new out ablation in last benefit patient believe challenging. healthy year. population quarter than here capability mapping and System industry the the of gaining adoption encouraging are expect their their growing persistent mappers We and while guidance, minimizing to This threefold physicians AcQBlate In product revenues We the curve XXXX destruction therapy higher total signals therapy with will septal same our unique and patients of delivered longstanding at in here mapping a is feature team
adoption. Catheter in our leading approval and Sensing for the Force behind right that therapy in and can trial and by XXXX Our of and for ablation efforts have activity. of ablation These also these going U.S., flutter our U.S. support excellent I the or AcQBlate to end the of well allow In early ablation to teams expect of we in you to our to in support week, enrollment atrial our of engine installed is clinical approval indicator workhorse EU Biotronik are in and progress the end XX and as ablation U.S. expect well enrollment our systems installing submission this complete partner as our have we gain made XXXX. RF commercial By Ablation the worldwide use trial systems the new therapeutic systems. update
we our enroll a ablation IDE as We study In in our our today, Czech first patients atrial Force study This also of of animal year fibrillation. for of one-year our XX mark we quality of addition a as patient follow our you given foundation field PFA milestone. to previously Also will apprised serve in critical patient from Republic. and application. eminently CE U.S. teams, our and our RF therapy, we the IDE keep enrollment study focus to end incredible of product this indication, plan progress. the pulsed will for involves trial up, flutter we our have ablation internal to discussed achieved CE U.S. the announced first and confidence had pursuing mark a and the by AcQ in of in this studies, first up physician enroll treated investigators, success our The
advocating single approval treatment patient deeper our a energy to device. approach format but ablation specific pulsed Catheter the guidance unlike of programs under We PFA, Sensing we utilizing PFA are focused competitor field are catheters, fast vast will that and This AcQMap essential to is with enhanced outside facilitates our program patients Diving by which on tailored a is to vein guide on Force on encouraged platform identification in for fast timelines, choice are into the strategy combined with to Ablation be delivery This deliberate be not so-called little approach isolation more majority enable as development veins, very yet of developments. platform line by PFA outcomes. are tailored AcQBlate we also effectively on approach to alone shot further therapeutic our the our of application with focal more system AF large with a thought pulmonary imaging longstanding providing fibrillation. atrial personalized and persistent a when areas to mapping pulmonary persistent of a our therapy that treat tachycardias complex target improve a mission end with to therapy treat
review So and in tenacious fruit summary, our is of careful reveals product focus very for bearing innovation our lines current the and on future bright a company. a future signals
become over heart our time. performance categories, are access will which We therapy strong important contributors increasingly and left revenue in seeing
slower than will training turn the for the and that, as on contributing performance. recent and mapping progressed improve factors expected, rate, an I teams. and to actively external physician as upgraded adoption our With has addressing business enhanced including to to Our the therapy somewhat we our update are environment software guidance experience well
due COVID to we a earnings access managing where three the August, were than instances, we country, including that as out. usual impacts, seasonality, well partly high Europe, in saw customers. vacations. seasonal expected have as resurgence, are have things how extended in During left long Arizona, The In lab weeks and many described COVID happen weeks. to the six last including found several where fluid, for quarter. of eight In operating COVID headwinds mapping U.S., cath than restrictions and Florida as staffing Europe played business of and risk hospital we where the very shortages to the call normal shutdowns, combination of as our concentration we this longer the pattern shuttered labs versus we as closed for in greater parts created Nevada, peak five and extended saw In related in broader to we landscape is exactly heart largely labs shutdowns
While we the of late magnitude to September, procedure lower than in the and saw capital was a procedure momentum base, installed sales and rebound lower insufficient offset in volumes planned disruptions. conversions
in here actively seeing and stability market we QX. general been have We monitoring trends are
in AcQMap Year-over-year decline of higher Turning and increased essentially sales a the and quarter compared an the of to procedure sequential seasonality. revenue good an to to second quarter quarter driven and prior globally year deferrals equipment results, growth versus disposable the related growth tied we was $X.X ended capital million, generated Systems. QX a third On procedure flat by COVID-XX volumes XXXX. basis, extended base installed offset sales higher of XX We with revenue. capital representing
strategic quarter, geography. the new certain During target to we the decision relocated with where or to users key position reposition utilization systems remove made below a and had
system. we looking us drive the where be extraordinarily will to U.S., the targeting In expectations. considerable simply we the that accounts focus higher we the human we QX we As optimize can of resources. grow system base, new adoption will installed cash does right to won't and where continue are new but our our This installations means to commercial mean our internal a our that make trailed utilization allow in also of we optimize in investment strategy, pace not install disciplined to placement, console
Europe hospital is technology centers. procedure support as seasonality number surges, a trends. access technology a patient predictable restrictions also rebounded of lengthy COVID from familiarity We in role installed saw in base the strong to and major physician and be to well as policies lab certain This throughput new have processes. post-COVID disruptions. administrative generally favoring we still as patient seeing backlogs Further, to In volumes clear are seems resulting of market limit regardless evaluations, play
We correspondingly access same fully management recognize this than expected. have severe regions, around, Europe volumes, Overall, in growth pods, while similar more has are major year improvement we Procedure high QX level parts where In hospital, on has told, a the our our but with in to a we in performance our the Moving we we decline accounts, accordingly. executed of sequentially discussed. call, and and by The strong had here volumes concentrated power versus across has quarter. the profile commercial initiatives. environment were on a our are what has am and business volumes proven not Southeastern own lower Central of in the Southwestern improved, the recruiting, saw on volumes The States. month-by-month concentration with All during encouraged business related responding At factors our utilization In are this to a quarter versus been third the at QX. what we pandemic we technology with a satisfied U.S. XX% global and representation. adoption This the are procedures, to areas. execution. previously not board year's Acutus throughout United headwind has have trajectory and quarter, performance and strength as saw respect led or last which the to procedure centered UK U.S. we we seeing that internal over stable external I team impact a procedure new the time, QX. have of take than Europe in
pace Going success ramp scale forward, patients. no and the initially shake likely we conviction drive and anticipated. strategy deeper provide physician, and our will In to value way this will our the expand also we penetration, The of long-term take to but account customers than and had the key model. is can our does longer replicate
mission and over As for large market. David happy differentiated cover turn to the our we valuable results. this to for the highly David? now I Q&A. our this long-term, And steadfast build it technology we in I'll to in be will company and in remain more growing financial this bring to detail